Determination of the structural basis for selective binding of Epstein- Barr virus to human complement receptor type 2

doi:10.1084/jem.174.6.1299

3rd Skeletal Biology and Medicine Symposium

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Martin, D. R.
	Articles by Ahearn, J. M.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Martin, D. R.
	Articles by Ahearn, J. M.


Social Bookmarking

	What's this?

ARTICLES

Determination of the structural basis for selective binding of Epstein- Barr virus to human complement receptor type 2

DR Martin, A Yuryev, KR Kalli, DT Fearon and JM Ahearn
Graduate Program in Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Epstein-Barr virus (EBV) is an oncogenic herpesvirus that selectively infects and immortalizes human B lymphocytes. One determinant of this narrow tropism is human CR2, the only viral receptor within the superfamily of proteins that contain short consensus repeats (SCRs). Human CR2 serves as a receptor for both C3dg and the gp350/220 glycoprotein of EBV, and binds the monoclonal antibody (mAb) OKB7, which blocks binding of both ligands to the receptor. In contrast, although murine CR2 is capable of binding human C3dg and this interaction can be blocked with the mAb 7G6, it does not bind OKB7 or EBV. We have determined the structural basis for absolute specificity of EBV for human CR2 through characterization of a panel of 24 human- murine chimeric receptors, all of which bind human C3dg. The results indicate that preferential binding of EBV to human CR2 is not due to unique amino acids that are capable of binding the virus, but reflects a distinct receptor conformation that can be achieved in murine CR2 with single amino acid substitutions in two discontinuous regions of the primary structure: replacement of proline at position 15 with the corresponding serine from human CR2, and elimination of a potential N- linked glycosylation site between SCR-1 and SCR-2. Furthermore, species- specific binding of EBV, OKB7, and 7G6 can all be manipulated through substitutions among residues 8-15, suggesting that this octapeptide is part of a structural determinant that is critical for binding of both viral and natural ligands to CR2.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Young, K. A., Chen, X. S., Holers, V. M., Hannan, J. P. (2007). Isolating the Epstein-Barr Virus gp350/220 Binding Site on Complement Receptor Type 2 (CR2/CD21). J. Biol. Chem. 282: 36614-36625 [Abstract] [Full Text]
Hutt-Fletcher, L. M. (2007). Epstein-Barr Virus Entry. J. Virol. 81: 7825-7832 [Full Text]
Asokan, R., Hua, J., Young, K. A., Gould, H. J., Hannan, J. P., Kraus, D. M., Szakonyi, G., Grundy, G. J., Chen, X. S., Crow, M. K., Holers, V. M. (2006). Characterization of Human Complement Receptor Type 2 (CR2/CD21) as a Receptor for IFN-{alpha}: A Potential Role in Systemic Lupus Erythematosus. J. Immunol. 177: 383-394 [Abstract] [Full Text]
Marchbank, K. J., Kulik, L., Gipson, M. G., Morgan, B. P., Holers, V. M. (2002). Expression of Human Complement Receptor Type 2 (CD21) in Mice During Early B Cell Development Results in a Reduction in Mature B Cells and Hypogammaglobulinemia. J. Immunol. 169: 3526-3535 [Abstract] [Full Text]
Prota, A. E., Sage, D. R., Stehle, T., Fingeroth, J. D. (2002). The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding. Proc. Natl. Acad. Sci. USA 99: 10641-10646 [Abstract] [Full Text]
Guthridge, J. M., Young, K., Gipson, M. G., Sarrias, M.-R., Szakonyi, G., Chen, X. S., Malaspina, A., Donoghue, E., James, J. A., Lambris, J. D., Moir, S. A., Perkins, S. J., Holers, V. M. (2001). Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface. J. Immunol. 167: 5758-5766 [Abstract] [Full Text]
Cherukuri, A., Cheng, P. C., Pierce, S. K. (2001). The Role of the CD19/CD21 Complex in B Cell Processing and Presentation of Complement-Tagged Antigens. J. Immunol. 167: 163-172 [Abstract] [Full Text]
Barel, M., Le Romancer, M., Frade, R. (2001). Activation of the EBV/C3d Receptor (CR2, CD21) on Human B Lymphocyte Surface Triggers Tyrosine Phosphorylation of the 95-kDa Nucleolin and Its Interaction with Phosphatidylinositol 3 Kinase. J. Immunol. 166: 3167-3173 [Abstract] [Full Text]
Bouillie, S., Barel, M., Frade, R. (1999). Signaling Through the EBV/C3d Receptor (CR2, CD21) in Human B Lymphocytes: Activation of Phosphatidylinositol 3-Kinase via a CD19-Independent Pathway. J. Immunol. 162: 136-143 [Abstract] [Full Text]
Prodinger, W. M., Schwendinger, M. G., Schoch, J., Kochle, M., Larcher, C., Dierich, M. P. (1998). Characterization of C3dg Binding to a Recess Formed Between Short Consensus Repeats 1 and 2 of Complement Receptor Type 2 (CR2; CD21). J. Immunol. 161: 4604-4610 [Abstract] [Full Text]
Buchholz, C. J., Koller, D., Devaux, P., Mumenthaler, C., Schneider-Schaulies, J., Braun, W., Gerlier, D., Cattaneo, R. (1997). Mapping of the Primary Binding Site of Measles Virus to Its Receptor CD46. J. Biol. Chem. 272: 22072-22079 [Abstract] [Full Text]